How well a cancer treatment works in everyday medical practice

This is a real-world study of melphalan flufenamide (Pepaxti®) combined with dexamethasone, a medication that was approved in Europe in 2022 for patients with multiple myeloma that has become resistant to standard treatments. Researchers want to understand how well this medication works and how safe it is when used in regular hospital and clinic settings, rather than in a controlled research environment. The study will track information from about 50 patients to see if the treatment helps control their cancer.

Multiple myeloma is a serious blood cancer that eventually stops responding to available treatments. This medication uses a new approach to attack cancer cells, but doctors need real-world information about how it performs in everyday practice and how to best manage side effects when patients receive it.